secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ventyx Biosciences, Inc. (—)
CIK:        0001851194
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056914
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Ventyx Q1 2024 net loss $38.6M; cash $302.6M; Phase 2a trials in H2 2024
------------------------------------------------------------------------

- Net loss of $38.6M in Q1 2024 vs $38.9M in Q1 2023; R&D $33.7M, G&A $8.0M.
- Cash, cash equivalents and marketable securities of $302.6M as of March 31, 2024; runway into H2 2026.
- Phase 2a trials of CNS-penetrant NLRP3 inhibitor VTX3232 to start H2 2024 in early Parkinson's and obesity with CV risk factors.
- Phase 2 topline data for TYK2 inhibitor VTX958 in Crohn's disease expected early H2 2024; enrollment completed.
- Positive Phase 2 CAPS data for VTX2735; seeking partner for VTX002 Phase 3 in ulcerative colitis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851194/000095017024056914/0000950170-24-056914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851194/000095017024056914/vtyx-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer